AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

LifeVantage Corporation (LFVN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

19.07

0.48 (2.58%)

At close: Feb 18, 2025, 3:59 PM

18.12

-5.03%

After-hours: Feb 18, 2025, 06:43 PM EST

undefined% (undefined)

Bid	n/a
Market Cap	-
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	n/a
PE Ratio (ttm)	n/a
Forward PE	n/a
Analyst	Buy

Ask	n/a
Volume	undefined
Avg. Volume (20D)	n/a
Open	undefined
Previous Close	undefined
Day's Range	undefined - undefined
52-Week Range	undefined - undefined
Beta	undefined

About LFVN

LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3...

[Show more]

Industry Packaged Foods

Sector Consumer Defensive

IPO Date Apr 7, 1994

Employees 222

Stock Exchange NASDAQ

Ticker Symbol LFVN

Website https://www.lifevantage.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for LFVN stock is "Buy." The 12-month stock price forecast is $30.5, which is a decrease of NaN% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

LifeVantage Corporation is scheduled to release its earnings on May 1, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

-16.49%

Lifevantage shares are trading lower following Q2 ... Unlock content with Pro Subscription

2 weeks ago

-4.21%

Lifevantage shares are trading lower. The company reported Q2 financial results.

News

6 days ago · marketbeat.com

GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends

The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to hit the market and disrupt the medical sector. These treatments are permitt...

1 week ago · seekingalpha.com

LifeVantage: Post-Earnings Selloff Provides Buying Opportunity

LifeVantage Corporation's Q2/FY2025 results were boosted by the successful launch of the MindBody GLP-1 system. LFVN revenues jumped by more than 40% on a sequential basis, while free cash flow of $8....

1 week ago · seekingalpha.com

LifeVantage Corporation (LFVN) Q2 2025 Earnings Call Transcript

LifeVantage Corporation (NASDAQ:LFVN ) Q2 2025 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Reed Anderson – Managing Director-ICR Steve Fife – President and Chief Executiv...

1 month ago · seekingalpha.com

Undercovered Dozen: Fannie Mae, Civitas Resources, LifeVantage, ZenaTech +

The 'Undercovered' Dozen series highlights lesser-covered stocks, offering investment ideas and encouraging discussion among investors. Pacifica Yield highlights Brookfield Infrastructure's subordinat...

1 month ago · seekingalpha.com

LifeVantage: Bold Move Into The GLP-1 Weight Loss Market Turns Out To Be A Major Winner - Buy

LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs from the likes of Zepbound and Ozempic. The recent launch has exceeded expectations by a wide margin. On Wedn...

2 months ago · benzinga.com

Top 3 Risk Off Stocks That May Collapse This Month

As of Dec. 20, 2024, three stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.